87.醫華生技 (台/泰) 與千葉大學附設醫院正式建立跨國策略合作關係

在千葉縣政府 的支持下醫華生技 (台/泰) 與日本頂尖醫療機構 千葉大學附設醫院正式建立跨國策略合作關係，為推動精準醫療發展邁出重要一步，進一步深化雙方在前沿醫療技術上的研究合作。

此次合作將把醫華生技專有的深度細胞分析技術導入日本嚴謹的臨床體系，加速聯合臨床研究，並深化 AI 與分子醫學的整合應用。透過更緊密的科研協作，雙方將共同推動創新技術從研發走向臨床實踐。

透過此合作，預期可提升複雜疾病（如癌症）的早期偵測能力，推動更精準的個人化治療，同時朝建立亞洲篩檢與治療監測新標準邁進。這不僅展現醫華生技持續拓展國際醫療合作的實力，也彰顯公司致力以創新技術改善全球醫療品質的承諾。 With the support of the Chiba Prefectural Government, CytoAurora (Taiwan/Thailand) has officially established a cross-border strategic partnership with Chiba University Hospital, a leading medical institution in Japan. This milestone marks a significant step forward in advancing precision medicine and further deepens both parties’ research collaboration in cutting-edge medical technologies.

Through this partnership, CytoAurora’s proprietary deep cell analysis technology will be introduced into Japan’s rigorous clinical environment to accelerate joint clinical research and strengthen the integration of AI and molecular medicine. With closer scientific collaboration, both sides aim to translate innovative technologies from research into real-world clinical practice.

This collaboration is expected to enhance early detection of complex diseases such as cancer, enable more precise personalized treatments, and work toward establishing new standards for screening and treatment monitoring across Asia. It not only demonstrates CytoAurora’s continued expansion of global medical partnerships but also underscores the company’s commitment to improving healthcare worldwide through innovation.